Author: admin

overstockArt.com Reveals Top 10 Most Popular Oil Paintings of 2023

overstockArt.com Reveals Top 10 Most Popular Oil Paintings of 2023
Masterpieces Unveiled: overstockArt.com’s Top 10 Oil Paintings of 2023 Illuminate the Beauty of Nature and the Tapestry of Human Connections

Wichita, Kansas – December 7th, 2023 – In celebration of artistic brilliance, overstockArt.com proudly presents the Top 10 Most Popular Art Masterpieces of 2023, a carefully curated selection that mirrors the collective sentiments and resilience of a world navigating through unprecedented times. 

The chosen masterpieces, gleaned from the discerning tastes of millions of visitors to overstockArt.com’s online art gallery and partner retailer sites, offer a poignant exploration of themes that resonated throughout the year — capturing the spectrum of hope, joy, sadness, and the universal quest for escape.

Top 10 Most Popular Artworks of 2023

     1. Discarded Roses – Pierre-Auguste Renoir

     2. Cliff Walk at Pourville – Claude Monet

     3. Grande Vase Di Fiori – Pierre-Auguste Renoir

     4. Starry Night – Vincent Van Gogh

     5. Cafe Terrace at Night – Vincent Van Gogh

     6. To The Highest Bidder – Harry Roseland

     7. The Storm on the Sea of Galilee – Rembrandt

     8. Italy at Dusk – Unknown

     9. The Kiss (Full View, Luxury Line) – Gustav Klimt

   10. Artist’s Garden at Giverny – Claude Monet

Nature scenes, both tranquil and chaotic, feature in the Top 10 list. Monet is featured twice with his calm yet colorful renderings of the Cliff Walk at Pourville and Artist’s Garden at Giverny, while crashing waves on Rembrandt’s Storm on the Sea of Galilee remind us of vulnerability – and hope. 

The selection is marked by a delicate balance of emotions, with Renoir’s “Discarded Roses” taking the top spot, and Roseland’s “To The Highest Bidder” delving into life, loss, and love. Meanwhile, Vincent Van Gogh’s “Starry Night” and “Café Terrace at Night” offer solace and quiet joy. 

Amitai Sasson, VP of eCommerce for overstockArt.com, commented on the significance of these artworks as a reflection of the global mood transitioning from the closed confinement of the pandemic era. 

“The Top 10 Oil Paintings of 2023 seamlessly marry nature’s splendor with the intricacies of human connections. In our pursuit of deeper bonds, a collective yearning for community, travel, and enriching experiences emerges.” 

“Relationships are also key in the Top 10 list: examine the sadness in ‘To The Highest Bidder’ and the passion and intensity of Klimt’s ‘The Kiss’. We know that relationships and self-reflection have been examined over the past year, and these artworks reflect that continued assessment,” he said. 

overstockArt.com stands as the foremost hand-painted art distributor in the United States. Recognized for its exceptional reproductions, these iconic paintings are not only available for purchase on the company’s website but are also prominently featured in many major retail stores. This expansive reach underscores overstockArt.com’s commitment to bringing artistic elegance to diverse spaces across the nation.

About overstockArt.com 

Founded in 2002, overstockArt.com is the web’s leading distributors of hand crafted wall art and museum quality framing. 

The online retailer and distributor’s goal is to make it easy and affordable for people to transform their space with high-end hand crafted wall art and museum quality framing. Recognized as a premiere source of fine art reproductions, overstockArt.com has expanded its offerings to include original canvas art prints, glass ornaments, ceramic tiles, specialty mirrors, and a newly unveiled line of decorative bowls.   

The company also owns and operates Artist Become (ArtistBe.com), the online community for contemporary artists from around the world. 

Headquartered in Wichita, Kansas, the retailer was named in Inc. Magazine’s 2010, 2011 and 2012 Inc. 5000 lists, Internet Retailer magazine’s 2012, 2014 Hot 100 list, and was recognized with the STELLAService Seal for Elite customer service. 

For more information, visit www.overstockArt.com

Media Contact
Company Name: OverstockArt.com
Contact Person: Amitai Sasson
Email: Send Email
Phone: (316) 631-3999
Country: United States
Website: https://www.overstockart.com/

GreenCare Designs LLC Featured in Real Estate Today for Innovative Pool and Spa Landscaping in Las Vegas

GreenCare Designs LLC, a Las Vegas pool and spa design company, is featured in Real Estate Today for its innovative, sustainable designs. The article highlights GreenCare’s focus on water conservation, using technologies like variable-speed pumps and rainwater harvesting. It also notes their use of UV-resistant materials and native plants for durability and low maintenance, alongside technology integration for automated control.

GreenCare Designs LLC, a leading pool and spa design company in Las Vegas, Nevada, has been featured in a prominent article in Real Estate Today. The article, titled “Transforming Backyards into Oasis: The Latest Trends in Pool and Spa Landscaping,” highlights GreenCare’s innovative approach to designing pools and spas in the challenging desert climate of Las Vegas.

The article emphasizes the importance of water conservation in desert pool design, a principle that GreenCare Designs LLC prioritizes in its projects. The company’s designs incorporate water-saving technologies such as variable-speed pumps, which are more energy-efficient and lose less water, and covers that significantly reduce evaporation. GreenCare is also pioneering the integration of rainwater harvesting systems and exploring natural pool designs that harmonize with the local ecosystem, demonstrating a strong commitment to environmental sustainability.

Another crucial aspect of pool and spa design in a desert environment is the selection of materials that can withstand the harsh sun and heat. GreenCare Designs LLC excels in using advanced materials like UV-resistant tiles and finishes, ensuring the longevity and aesthetic appeal of their pools and spas. The company’s expertise extends to selecting heat-reflective materials for decking and surrounding areas, enhancing comfort and sustainability.

Landscaping around the pool and spa is another area where GreenCare Designs LLC shows its expertise. The company utilizes xeriscaping and native desert plants to create a low-maintenance, water-conserving, and visually stunning environment. These landscaping choices not only add to the beauty of the outdoor space but also contribute to creating a natural habitat for local wildlife.

Technology integration is another hallmark of GreenCare’s pool and spa designs. Automated systems for filtration, heating, and lighting are standard in their projects, optimized for energy efficiency. Smart technology allows homeowners to control various aspects of their pool and spa remotely, adding convenience and ensuring optimal operation.

The article concludes by praising GreenCare Designs LLC for its balanced approach to luxury and sustainability in pool and spa design. The company’s innovative solutions cater to the unique demands of desert environments, providing not only functional and eco-friendly spaces but also serene escapes in the heart of Las Vegas.

GreenCare Designs LLC’s feature in Real Estate Today is a testament to their ingenuity, adaptability, and commitment to sustainable practices in modern landscaping. 

To read the full article, click here.

Media Contact
Company Name: GreenCare
Email: Send Email
City: Las Vegas
State: Nevada
Country: United States
Website: https://greencare.net/

HedgeFundBank Confirms Establishment of a Branch in South Africa, Anticipated to Boost Employment and Investment

On November 22, as a globally emerging financial fund platform, HedgeFundBank will establish a branch in South Africa for its financial fund business, bringing new employment and investment models to the local area. This is expected to enhance the capabilities of local enterprises and drive a transformation in local employment and investment methods.

According to a data report from HedgeFundBank, the Southern African region experienced a slowdown in economic growth in the past year. In 2022, the GDP growth in Southern Africa was only 2.7%, much lower than the global and African averages of 3.4% and 3.8%, respectively. South Africa, its largest economy, faced multiple challenges. The economic growth in Southern Africa further slowed down to 1.6% in 2023. However, with the entry and assistance of HedgeFundBank, the economic situation in South Africa is expected to improve slightly in 2024, with GDP rising to 3.1%.

More and more countries consider the development of the digital financial economy as a key to enhancing their economic competitiveness and achieving economic transformation. African countries are no exception, as evidenced by market performance. HedgeFundBank’s entry into South Africa will benefit the entire African continent. The platform is expected to reap considerable returns from Africa’s vast economic potential and calls for expanding partnerships and increasing investments to promote sustainable and inclusive growth on the continent. HedgeFundBank is also very willing to employ locals.

As the industry matures, more platforms and tools support digital creators in various ways, from simplifying content distribution to providing profit opportunities. The growing online work mode will create more job opportunities, and the potential of the online economy in creating employment and driving economic growth will be further explored. For HedgeFundBank, conducting business in South Africa, a market with vast potential, will also be a new point of business growth.

As an industry leader, HedgeFundBank provides top-notch services and has been rated as investment-grade BBB by Standard & Poor’s. It serves over 200 banks and brokerage firms and more than 400 financial intermediary institutions in over 80 countries and regions, offering trading investment services and solutions. Its successful entry into Africa will enable HedgeFundBank to explore and execute important partnerships in the region and continue to strengthen inclusive financial exchanges and cooperation with other national fund institutions.

For South Africa, HedgeFundBank will help shape a pro-poor economic growth model, drive local industrial upgrading, and assist the local economy and workers with employment needs. From HedgeFundBank’s corporate culture, the company is also willing to provide local users with good development opportunities.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: HedgeFundBank
Contact Person: Thomas Grace
Email: Send Email
Country: South Africa
Website: https://hedgefundbank.com/

Credit 2 Millionz Empowers Immigrants and US Residents To Achieve Financial Freedom and Business Success

Credit 2 Millionz is revolutionizing financial empowerment for immigrants and US residents. Founder Eduardo Soto’s journey from immigrant to successful entrepreneur forms the foundation. Unique offerings include strategies for securing business funding with aged corporations. Their programs educate on the US credit system, enabling clients to achieve a 750+ credit score in months and uncover travel hacks for luxury adventures.

Eduardo Soto, the visionary behind Credit 2 Millionz, understands the challenges immigrants and US residents face when navigating the complex world of credit. In 2004, Eduardo immigrated from Colombia to Canada and embarked on a transformative journey in the oil and gas industry, dedicating himself tirelessly for 12 years. Throughout his experience, he recognized the importance of establishing a solid credit history.

Through perseverance and determination, Eduardo successfully established credit in the United States. He accomplished this by amassing nearly $700,000 in funding during a single round, which allowed him to embark on a world-traveling adventure. Given his passion for sharing knowledge and expertise, Eduardo finds great fulfillment in assisting others in leveraging the credit system to realize their aspirations.

Credit 2 Millionz offers three programs: Credit 2 Millionz 101 (Free course you can access HERE), Credit 2 Millionz Business Launch Method, and Credit 2 Millionz 6 Week Mentorship.

Credit 2 Millionz stands out with several unique selling points:

–  Eduardo, a Latin American immigrant, is a powerful testament to the brand’s mission through his triumphant journey of achieving financial success and ultimately leaving his job.

–  Credit 2 Millionz provides strategies for business funding, explicitly focusing on obtaining funding with aged corporations and newer entrepreneurs seeking capital to get their business off the ground. This valuable resource sets them apart from competitors who often overlook this aspect in their teachings.

–  The brand shares its experience with immigrants in the US and individuals from Canada, Australia, UK, Singapore, Colombia, Venezuela, Spain, Mexico and seeking to help more business owners around the world. This valuable information helps them understand how to utilize the US credit system effectively, even as a non US resident. 

–  Eduardo possesses credit in Canada, the US, and Colombia. This unique qualification allows him to assist a diverse clientele with multinational credit needs. 

–  Communicating in Spanish is valuable, especially for the Spanish-speaking community. It provides numerous advantages and opens up opportunities for connection and understanding.

The company appeals to a target audience of individuals aged 18-40, primarily of Hispanic or immigrant background. This audience shares a strong interest in luxury travel, adventures, credit, and business credit. The brand caters to corporate professionals seeking to enhance their lifestyles, business builders aiming to expand their ventures, and investors searching for funding opportunities.

Eduardo Soto envisions Credit 2 Millionz as a solution that bridges the gap between business and lifestyle for entrepreneurs while addressing the concerning fact that 83% of companies fail due to insufficient funding or cash flow. His aim with Credit 2 Millionz is to empower individuals worldwide by unlocking the full potential of the US credit system.

Individuals can learn more by accessing the official Instagram profile.

Media Contact
Company Name: Credit 2 Millionz
Contact Person: Eduardo Soto
Email: Send Email
Country: United States
Website: https://www.instagram.com/iamedsoto/

B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics

DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the B-Cell Lymphomas pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Lymphomas pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the B-Cell Lymphomas Pipeline Report

  • DelveInsight’s B-Cell Lymphomas pipeline report depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-Cell Lymphomas treatment.
  • The leading companies working in the B-Cell Lymphomas Market include Oncternal Therapeutics Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company Ltd, TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others.
  • Promising B-Cell Lymphomas Pipeline Therapies in the various stages of development include Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, Maplirpacept (PF-07901801), Glofitamab, Obinutuzumab, and others.
  • December 2023: Genmab announced a study of Phase 2 clinical trials for Epcoritamab and Lenalidomide. The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
  • December 2023: AbbVie announced a study of Phase 3 clinical trials for Epcoritamab, Cyclophosphamide, Rituximab and Vincristine. A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

 

Request a sample and discover the recent advances in B-Cell Lymphomas Treatment Drugs @ B-Cell Lymphomas Pipeline Outlook Report

 

In the B-Cell Lymphomas pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, B-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

B-Cell Lymphomas Overview

B-cell lymphoma is a type of non-Hodgkin lymphoma that originates in the B-cells. It is the most common type of lymphoma and about 85% of all lymphomas in the United States are B-cell. Common symptoms associated with lymphoma include painless enlargement of one or more lymph node areas, fever, night sweats, and weight loss. Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma.

 

Find out more about B-Cell Lymphomas Treatment Landscape @ Drugs for B-Cell Lymphomas Treatment

 

B-Cell Lymphomas Emerging Drugs Profile

  • Odronextamab: ZAI Lab
  • NKTR-255: Nektar Therapeutics
  • Zilovertamab Vedotin: Merck Sharp & Dohme LLC
  • Abexinostat: Xynomic Pharmaceuticals

 

B-Cell Lymphomas Pipeline Therapeutics Assessment

There are approx. 160+ key companies which are developing the B-Cell Lymphomas therapies. The B-Cell Lymphomas companies which have their B-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, ZAI Lab.

 

DelveInsight’s B-Cell Lymphomas Pipeline report covers around 170+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging B-Cell Lymphomas Pipeline Therapies @ B-Cell Lymphomas Clinical Trials Assessment

 

Scope of the B-Cell Lymphomas Pipeline Report

  • Coverage- Global
  • B-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • B-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • B-Cell Lymphomas Companies- Oncternal Therapeutics Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company Ltd, TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others.
  • B-Cell Lymphomas Pipeline Therapies- Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, Maplirpacept (PF-07901801), Glofitamab, Obinutuzumab, and others.

 

Dive deep into rich insights for new drugs for B-Cell Lymphomas Treatment, Visit @ B-Cell Lymphomas Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. B-Cell Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. B-Cell Lymphoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Odronextamab: ZAI Lab
  9. Drug profiles in the detailed report…..
  10. Mid-Stage Products (Phase II)
  11. Abexinostat: Xynomic Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. TG 1801: TG Therapeutics Inc.
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. B-Cell Lymphoma Key Companies
  18. B-Cell Lymphoma Key Products
  19. B-Cell Lymphoma- Unmet Needs
  20. B-Cell Lymphoma- Market Drivers and Barriers
  21. B-Cell Lymphoma- Future Perspectives and Conclusion
  22. B-Cell Lymphoma Analyst Views
  23. B-Cell Lymphoma Key Companies
  24. Appendix

 

For further information on the B-Cell Lymphomas Pipeline Therapeutics, reach out @ B-Cell Lymphomas Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Lymphomas Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics

Alzheimer’s Disease Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023

DelveInsight’s, “Alzheimer’s Disease Pipeline Insights 2023” report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in Alzheimer’s Disease pipeline landscape. It covers the Alzheimer’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alzheimer’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Alzheimer’s Disease Pipeline Report

  • DelveInsight’s Alzheimer’s disease pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Alzheimer’s disease treatment.
  • The leading companies working in the Alzheimer’s disease Market include Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
  • Promising Alzheimer’s disease Pipeline Therapies in the various stages of development include PM012, Lecanemab 2.5 mg/kg, Aricept (donepezil SR 23 mg), AL002, Rivastigmine transdermal patch, Simufilam, and others.
  • November 2023: UCB Biopharma SRL announced a study of Phase 2 clinical trials for Bepranemab. The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer’s Disease (AD).
  • November 2023: Alector Inc. announced a study of Phase 2 clinical trials for AL002. This is a Phase 2, randomized, parallel-group, long-term extension (LTE), dose-blind, multicenter study to evaluate the long-term safety and efficacy of AL002 in participants with Early Alzheimer’s Disease. The study is a multicenter, global trial that will enroll participants who completed the planned treatment period in AL002-2 (parent study).
  • September 2023: Cassava Sciences Inc. announced a study of phase 3 clinical trials for Simufilam.The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 76-week, repeat-dose oral administration in participants with mild-to-moderate AD.
  • September 2023: Alector Inc. announced a study of phase 2 clinical trials for AL002. A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer’s Disease.

 

Request a sample and discover the recent advances in Alzheimer’s Disease Treatment Drugs @ Alzheimer’s Disease Pipeline Outlook Report

 

In the Alzheimer’s disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Alzheimer’s disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Alzheimer’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Alzheimer’s Disease Overview

Dementia is a general term that refers to a decline in cognitive ability severe enough to interfere with activities of daily living. Alzheimer’s disease (AD) is the most common type of dementia, accounting for at least two-thirds of cases of dementia in people age 65 and older. Alzheimer’s disease is a neurodegenerative disease with insidious onset and progressive impairment of behavioral and cognitive functions including memory, comprehension, language, attention, reasoning, and judgment.

 

Find out more about Alzheimer’s Disease Treatment Landscape @ Drugs for Alzheimer’s Disease Treatment

 

Alzheimer’s Disease Emerging Drugs Profile

  • Nilotinib: KeifeRx
  • AR1001: AriBio Co., Ltd.
  • LY3372689: Eli Lilly & Co

 

Alzheimer’s Disease Pipeline Therapeutics Assessment

There are approx. 150+ key companies which are developing the therapies for Alzheimer’s Disease. The Alzheimer’s Disease companies which have their Alzheimer’s Disease drug candidates in the most advanced stage, i.e. phase III include, KeifeRx.

 

DelveInsight’s Alzheimer’s Disease pipeline report covers around 160+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Alzheimer’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Alzheimer’s Disease Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Alzheimer’s Disease Pipeline Therapies @ Alzheimer’s Disease Clinical Trials Assessment

 

Scope of the Alzheimer’s Disease Pipeline Report

  • Coverage- Global
  • Alzheimer’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Alzheimer’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Alzheimer’s Disease Companies- Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
  • Alzheimer’s disease Pipeline Therapies- PM012, Lecanemab 2.5 mg/kg, Aricept (donepezil SR 23 mg), AL002, Rivastigmine transdermal patch, Simufilam, and others.

 

Dive deep into rich insights for new drugs for Alzheimer’s Disease Treatment, Visit @ Alzheimer’s Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Alzheimer’s Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Alzheimer’s Disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Nilotinib: Novartis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. LY3372689: Eli Lilly & Co.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Product Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Alzheimer’s Disease Key Companies
  18. Alzheimer’s Disease Key Products
  19. Alzheimer’s Disease- Unmet Needs
  20. Alzheimer’s Disease- Market Drivers and Barriers
  21. Alzheimer’s Disease- Future Perspectives and Conclusion
  22. Alzheimer’s Disease Analyst Views
  23. Alzheimer’s Disease Key Companies
  24. Appendix

 

For further information on the Alzheimer’s Disease Pipeline Therapeutics, reach out @ Alzheimer’s Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alzheimer’s Disease Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023

Asthma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sanofi, Zura Bio Ltd., AstraZeneca, and others.

DelveInsight’s, “Asthma Pipeline Insight 2023” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Asthma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Asthma Pipeline Report

  • DelveInsight’s Asthma pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Asthma treatment.
  • The leading companies working in the Asthma Market include Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, and others.
  • Promising Asthma Pipeline Therapies in the various stages of development include DUPIXENT®, Tezepelumab, MEDI9929, Revamilast, Benralizumab, AZD7594, GSK3511294 (Depemokimab), and others.
  • November 2023: AstraZeneca announced a study of Phase 3 clinical triails for Tezepelumab. This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 396 participants will be randomized regionally (China/non-China). Participants will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.
  • December 2023: Sanofi announced a study of Phase 4 clinical trials for Dupilumab. This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.

 

Request a sample and discover the recent advances in Asthma Treatment Drugs @ Asthma Pipeline Outlook Report

 

In the Asthma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Asthma Overview

Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen.

 

Find out more about Asthma Treatment Landscape @ Drugs for Asthma Treatment

 

Asthma Emerging Drugs Profile

  • Dexpramipexole: Areteia Therapeutics
  • TQC2731: Chia Tai Tianqing Pharmaceutical Group
  • SHR-1703: Jiangsu HengRui Medicine

 

Asthma Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the Asthma therapies. The Asthma Companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Areteia Therapeutics.

 

DelveInsight’s Asthma pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Asthma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Asthma Pipeline Therapies @ Asthma Clinical Trials Assessment

 

Scope of the Asthma Pipeline Report

  • Coverage- Global
  • Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Asthma Companies- Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, and others.
  • Asthma Pipeline Therapies- DUPIXENT®, Tezepelumab, MEDI9929, Revamilast, Benralizumab, AZD7594, GSK3511294 (Depemokimab), and others.

 

Dive deep into rich insights for new drugs for Asthma Treatment, Visit @ Asthma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Asthma Executive Summary
  3. Asthma: Overview
  4. Asthma Pipeline Therapeutics
  5. Asthma Pipeline Therapeutic Assessment
  6. Asthma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. PT-027: Avillion LLP
  9. Mid Stage Products (Phase II/III)
  10. PT001: Pearl Therapeutics (AstraZeneca)
  11. Mid Stage Products (Phase II)
  12. FP 025: Foresee Pharmaceuticals
  13. Early Stage Products (Phase I/II)
  14. AQ-001S: Aquilon Pharmaceuticals S.A
  15. Early Stage Products (Phase I)
  16. Itolizumab (EQ001): Equillium
  17. Preclinical and Discovery Stage Products
  18. KBP7026: KBP Biosciences
  19. Inactive Products
  20. Asthma Key Companies
  21. Asthma Key Products
  22. Asthma- Unmet Needs
  23. Asthma- Market Drivers and Barriers
  24. Asthma- Future Perspectives and Conclusion
  25. Asthma Analyst Views
  26. Asthma Key Companies
  27. Appendix

 

For further information on the Asthma Pipeline Therapeutics, reach out @ Asthma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sanofi, Zura Bio Ltd., AstraZeneca, and others.

Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, and Others.

DelveInsight’s, “Bladder Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Bladder Cancer Pipeline Report

  • DelveInsight’s Bladder Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
  • The leading companies working in the Bladder Cancer Market include CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., Nektar Therapeutics, Hamlet Pharma AB, Asieris Pharmaceuticals, Wuhan Binhui Biotechnology, Pfizer, Taizhou Hanzhong biomedical co. Ltd, Hoffmann-La Roche, Protara Therapeutics, AstraZeneca, CicloMed LLC, enGene, Inc., Emtora Biosciences, Qilu Pharmaceutical Co., Ltd., Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, Lindis Biotech, Incyte Corporation, Eli Lilly and Company, Daiichi Sankyo, Nektar Therapeutics, Pieris Pharmaceuticals, Inc., Istari Oncology, Inc., BeiGene, Vyriad, Inc., Adlai Nortye Biopharma Co., Ltd., Kyowa Kirin, Inc., Infinity Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Fusion Pharmaceuticals Inc., GI Innovation, Inc., SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, and others.
  • Promising Bladder Cancer Pipeline therapies in the various stages of development include Hexaminolevulinate hydrochloride, CG0070, Pembrolizumab Injection, ADSTILADRIN, Enfortumab Vedotin, and others.
  • October 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials of Pembrolizumab and Enfortumab Vedotin. This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone.
  • October 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab and Bempegaldesleukin. The purpose of the study is to see if treatment with nivolumab plus bempegaldesleukin or nivolumab alone, before and after surgery to remove the bladder, is more effective than surgery alone in participants with high-risk urothelial cancer, including muscle-invasive bladder cancer who are not able to receive cisplatin chemotherapy. A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible.
  • October 2023 Ferring Pharmaceuticals announced a study of Phase 3 clinical trials for FE 999326. To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC. A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC).
  • October 2023: Janssen Research & Development LLC announced a study of Phase 3 clinical trials for TAR-200 and Cetrelimab. The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).  The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG.

 

Request a sample and discover the recent advances in Bladder Cancer Treatment Drugs @ Bladder Cancer Pipeline Outlook Report

 

In the Bladder Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Bladder Cancer NDA approvals (if any), and product development activities comprising the technology, Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Bladder Cancer Overview

Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men.

 

Find out more about Bladder Cancer Therapeutics Assessment @ Bladder Cancer Preclinical and Discovery Stage Products

 

Bladder Cancer Emerging Drugs Profile

  • CG0070: CG Oncology
  • N-803: ImmunityBio
  • UGN-102: UroGen
  • Trilaciclib: G1 Therapeutics

 

Bladder Cancer Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the Bladder cancer therapies. The Bladder cancer companies which have their Bladder cancer drug candidates in the most advanced stage, i.e. phase III include, CG Oncology.

 

DelveInsight’s Bladder Cancer pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Bladder Cancer Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Learn more about the emerging Bladder Cancer Pipeline Therapies @ Bladder Cancer Clinical Trials Assessment

 

Scope of the Bladder Cancer Pipeline Report

  • Coverage- Global
  • Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Bladder Cancer Companies- CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co.,Ltd., Nektar Therapeutics, Hamlet Pharma AB, Asieris Pharmaceuticals, Wuhan Binhui Biotechnology, Pfizer, Taizhou Hanzhong biomedical co. Ltd, Hoffmann-La Roche, Protara Therapeutics, AstraZeneca, CicloMed LLC, enGene, Inc., Emtora Biosciences, Qilu Pharmaceutical Co., Ltd., Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, Lindis Biotech, Incyte Corporation, Eli Lilly and Company, Daiichi Sankyo, Nektar Therapeutics, Pieris Pharmaceuticals, Inc., Istari Oncology, Inc., BeiGene, Vyriad, Inc., Adlai Nortye Biopharma Co., Ltd., Kyowa Kirin, Inc., Infinity Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Fusion Pharmaceuticals Inc., GI Innovation, Inc., SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, and others.
  • Bladder Cancer Pipeline therapies- Hexaminolevulinate hydrochloride, CG0070, Pembrolizumab Injection, ADSTILADRIN, Enfortumab Vedotin, and others.

 

Dive deep into rich insights for new drugs for Bladder Cancer Treatment, Visit @ Bladder Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Bladder cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Bladder cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. CG0070: CG Oncology
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Trilaciclib: G1 Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. MV-NIS: Vyriad
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. FEP 633: PRISM BioLab
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Bladder cancer Key Companies
  21. Bladder cancer Key Products
  22. Bladder cancer- Unmet Needs
  23. Bladder cancer- Market Drivers and Barriers
  24. Bladder cancer- Future Perspectives and Conclusion
  25. Bladder cancer Analyst Views
  26. Bladder cancer Key Companies
  27. Appendix

 

For further information on the Bladder Cancer Pipeline therapeutics, reach out to Bladder Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, and Others.

Button Energy Fuels Growth: Expanding Operations to Deliver Enhanced Energy Solutions

Button Energy Fuels Growth: Expanding Operations to Deliver Enhanced Energy Solutions

In a significant move to bolster its service offerings and reach, Button Energy, a reputable Pennsylvania fuel and energy solutions provider, has announced an ambitious expansion of its operations. This development marks a new era for the company, which has been a trusted name in the provision of home and commercial oil and propane in Central and Northeast Pennsylvania for over 90 years.

Residential Services – Propane & Heating Oil Delivery

Button Energy has long been synonymous with residential propane delivery, offering reliable and personable service for both heating oil and propane delivery. The company takes pride in its ability to offer competitive pricing without compromising on the quality of service. As part of the expansion, homeowners can expect enhanced services, including propane delivery for a variety of uses such as whole house heat, fireplaces, water heaters, dryers, and even lighting​​​​.

To further assist its customers, Button Energy offers automatic delivery and a “Never Run Out Guarantee”, that provides a refund and emergency delivery service if a customer should run out of heating oil. Button Energy keeps fuel costs affordable and makes fuel delivery easy, while also offering a range of pricing plans and budgeting options for client flexibility.

Commercial Fuel Delivery and Wholesale Fuel Supply

Button Energy is set to increase its footprint in the commercial sector, providing an array of petroleum energy products for wholesale purchase including: heating oil, propane, gasoline, dyed diesel, and more. Button Energy can deliver fuel to your business, farm, restaurant, construction site or industrial complex and serves the commercial community with the same reliability and competitive pricing it offers to residential customers​​.

An exciting development in the commercial domain is the enhancement of Button Transportation services. Equipped with a fleet of specialized vehicles and common carrier transport, Button Energy is poised to deliver multiple fuel products in a single delivery. This service is particularly beneficial for retail gas stations, utility companies, municipalities,construction companies and railroads, offering them the highest quality product at the lowest possible cost​​.

Button Energy’s Services at a Glance

Residential Propane and Heating Oil Delivery: Button Energy provides reliable and affordable delivery of heating oil and propane to homes, and manages usage to ensure efficient delivery of fuel.

Fleet & Construction Fueling: Button Energy offers tailored solutions for both mobile and on-site fleet fueling, which is ideal for powering industrial equipment, generators, tanks, and truck fleets.

Fuel Transports: The company specializes in loading, transporting, and delivering petroleum products, ensuring safe, professional, affordable and timely delivery service. Their clientele ranges from large wholesalers to small convenience store operators.

Wholesale Fuel for Purchase: Button Energy supplies a wide range of petroleum products on a wholesale basis, providing a reliable and affordable source of petroleum energy products to retailers.

About Button Energy

Button Energy is a distinguished provider of energy solutions in Central and Northeast Pennsylvania, specializing in residential and commercial oil and propane services. They are known for their reliable and affordable delivery of petroleum energy products, including heating oil, propane, gasoline, and dyed diesel. The company prides itself on offering personable service coupled with competitive pricing, tailored to meet the diverse needs of both homeowners and businesses. Additionally, Button Energy provides a variety of services such as fleet fueling, construction fueling, and wholesale fuel delivery, emphasizing their commitment to comprehensive energy solutions. Their recent expansion initiatives further demonstrate their dedication to enhancing service offerings and reaching a broader customer base. Button Energy has a long history spanning 90 years of excellent service making it the premier Pennsylvania Propane Company. 

Media Contact
Company Name: Button Energy
Email: Send Email
Address:116 S. Main Rd
City: Mountain Top
State: Pennsylvania
Country: United States
Website: https://buttonoil.com/

Alexander Dolgin: Trailblazer in Technology, Real Estate, and Academia

Renowned for his innovative spirit, Alexander Dolgin has made significant strides in technology, real estate, and academia. From founding the Soyuznikhrom metallurgical holding and the Urban Group to pioneering digital services with ‘Litres’ and Imhonet.ru, Dolgin’s journey is marked by resilience and versatility. His contributions as a professor and researcher further accentuate his diverse expertise.

Alexander Dolgin has continually demonstrated a unique prowess in bridging technology, real estate, and scientific research. Born in Kiev on January 17, 1961, Dolgin’s journey from a physics student at the National University of Science and Technology (NITU MISIS) to a leading business magnate and scholar is remarkable.

In 1983, Dolgin graduated with a major in “the physics of metals,” laying the groundwork for a career that would span various sectors and impact them. His academic journey didn’t stop there; he progressed to become a Candidate of Technical Sciences and an author of more than 300 scientific and popular articles. Dolgin’s early career saw him directing a laboratory of new technologies.

From 1992 to 2006, Dolgin led Soyuznikhrom, a metallurgical holding he founded in 1992. This venture included the Vladimir plant of precision alloys, the Factory of Metal Hoses, and NPO Magneton, marking his first significant success in the business world.

In 2007, Dolgin founded the Urban Group, a development company, which, under his leadership, emerged as a significant market player, demonstrating his ability to innovate and adapt across diverse sectors. However, the journey was challenging, as in 2018, the Urban Group faced complications and was closed.

Parallel to his real estate ventures, Dolgin’s passion for technology and innovation led him to found Imhonet.ru, a recommendatory Internet service, in 2007. Imhonet.ru pioneered the Russian internet space but ceased operations in 2016 after not finding a way to monetize people’s recommendations.

Significant contributions to academia also mark Dolgin’s career. Since 2003, he has been a professor at the Higher School of Economics National Research University, blending practical industry experience with academic insights. In 2001, he established the “Culture Pragmatics” scientific research foundation, further highlighting his commitment to scientific and cultural development.

Alexander Dolgin owns several companies, including DCA (Digital Centric Alliance), Openstat (an Internet counter), and DSL. His diverse portfolio reflects a commitment to staying at the forefront of technological and digital innovation.

As a visionary leader, Dolgin continues to explore new horizons and expand his impact across various sectors. His journey, marked by resilience, innovation, and a continuous quest for knowledge, inspires newcomer entrepreneurs and industry veterans. Since 2001, he has been an ideologist of donations, seeking their institutionalization.

Media Contact
Company Name: Alexander Dolgin
Contact Person: Sergey
Email: Send Email
Country: Cyprus
Website: https://tadviser.com/index.php/Person:Dolgin_Alexander_Borisovich